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1.

Behavioral, educational, and family therapies combined with early recognition and intervention is the
current standard for management of children with autism spectrum disorder (ASD). Despite these
interventions, many children still retain behavioral disturbances that negatively impact their quality of
life. Researchers have estimated more than 50% of adolescents with ASD are prescribed medications
to help them manage behaviors or comorbid conditions, over half of whom experience psychotropic
polypharmacy. Only risperidone and aripiprazole are FDA-approved for ASD patients, although
numerous medications are used "off-label" and in combination to treat behavioral disturbances. There
is limited research supporting greater therapeutic benefits than side effects of other atypical
antipsychotics, SSRIs, SNRIs, stimulants, and TCAs for ASD management. The studies currently
available have shown possible efficacy for "off-label" drugs, but the evidence is far from
comprehensive or conclusive. Further clinical investigation is needed in order to develop standards of
care for the use of psychotropic pharmaceuticals to treat maladaptive behaviors associated with ASD.

Introduction
Autism spectrum disorder (ASD) is a neurological condition marked by qualitative difficulties in
social interaction, difficulties in communication, repetitive behavior, and a narrow range of
interests. ASD is regarded as one of the most prevalent developmental disorders, affecting
approximately 1 in 44 children in the United States. The current treatment recommendations involve
early intervention with educational therapies such as speech therapy, sensory integration therapy, and
auditory therapy. This has proven to be effective, but some individuals with ASD have particular
challenges with overactivity, impulsiveness, tantrums, aggression, and self-injury. These behaviors
strain caregivers and limit the child's ability to participate in educational therapies to the fullest. Due
to this, some clinicians have turned to adjuvant pharmacotherapy. Currently, the FDA has only
approved risperidone and aripiprazole, both antipsychotic drugs, for the treatment of irritability in
patients with ASD. The effectiveness of these medications is controversial among practitioners, and
thus, other pharmacological management strategies have been adopted. This study discusses the
research and proposals about the potential effectiveness of pharmacological adjuvant therapies and
their associated risks for children with ASD.
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Conclusion
The best practice for medical practitioners
managing ASD-related behavioral issues is to
remain as educated as possible about different
possible treatments, especially if the only two FDA
approved antipsychotics are not well tolerated. It is
extremely important to work closely with families
and keep them educated with reasonable
expectations for different drug treatments. Of the
potential risks, it is particularly crucial to discuss
which drugs have an inherent risk of causing
drowsiness and sedation for school-aged
children. Likewise, it is crucial for practitioners
and families to express their experiences with
different ASD treatments in hopes more research is
conducted in the future. The role of
pharmacological management in ASD has an
incredible amount of potential, but is far from
comprehensive and needs further clinical
investigation in order to have a maximized impact
on the lives of patients and caregivers.

Figure 1. Approach to prescribing medication to manage ASD
in children

Table 1. Comparison of Results
Study

Methods
Literature Search
• Performed in December 2021 using Science Direct, Google Scholar, and PubMed
• Search Terms: “ autism spectrum disorder OR ASD OR pervasive developmental
disorder OR autism AND drug therapy OR pharmacologic therapy
OR pharmacological treatment OR pharmacologic management OR medication”
• Inclusion Criteria:
• Relevance to the special interest topic
• Published in peer-reviewed journal
• Published 1993 or later
• Clinical trials involving pediatric patients (mean age < 21 years old)
• Emphasis on studies with a randomized & controlled design
• Exclusion Criteria:
• Studies without documented clinical trial
• Clinical trials involving animals
• Clinical trials involving adults (mean age > 21 years old)

Due to the wide variety of treatment options, the inherent complexity of psychotropic medications, and a lack of clear guidance, choosing
a treatment plan can be a daunting task for patients and their families. While individual decisions on treatment plans must be made by the
clinicians in conjunction with the patients, more research should be performed to build a repository of knowledge for clinicians to draw
from. Many of the discussed studies show statistically significant improvements in aberrant behaviors, but broader studies need to be
performed with larger sample sizes to accurately assess the risks of negative side effects. Without this complete risk profile, it can be
difficult to predict how a certain medication will impact a child without relying on trial and error. Additionally, more research needs to be
done on the mechanisms of action of many psychotropic drugs, particularly in regard to its impact on the pathology of ASD, which also
requires more research to understand. Despite these challenges, patients and their families can be hopeful that these "off-label"
medications can provide some relief of symptoms.

Medication

Therapeutic Effects

Side Effects
• Risperidone therapy was associated with an average weight
gain of 2.7+/-2.9 kg, as compared with 0.8+/-2.2 kg with
placebo (P<0.001).
• Increased appetite, fatigue, drowsiness, dizziness, and
drooling were more common in the risperidone group than
in the placebo group (P<0.05 for each comparison)
• Extrapyramidal symptoms incidence: 27.5%
• Fatigue, vomiting, somnolence, tremor, presyncope, and
aggression
• Impulse-control problems such as gambling behavior and
binge eating

1 and 2

Risperidone
(Risperdal)

▪ Aberrant Behavior Checklist Irritability Subscale Scores: 56.9% reduction in the Irritability
score for treatment group, as compared with a 14.1 percent decrease in the placebo group
(P<0.001)
▪ Aberrant Behavior Checklist Irritability Subscale Scores: 64% improvement over in the
irritability score for treatment group, almost double that of placebo-treated subjects (31%)

3

Aripiprazole
(Abilify)

▪ Aberrant Behavior Checklist Irritability Subscale Scores: 14.4-point reduction in the irritability
score for treatment group, as compared with an 8.4-point decrease in the placebo (P<0.05)

4

Olanzapine
(Zyprexa)

• Clinical Global Impressions (CGI) Improvement Item: 5 out of 6 patients rated as responders
• Children's Psychiatric Rating Scale (CPRS): Subjects showed improvement on the CPRS Autism • Weight gain and sedation
Factor (F 1,9 = 24.4, P=0.0008)
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Lurasidone
(Latuda)

• Aberrant Behavior Checklist Irritability Subscale Scores: Lurasidone did not significantly
differentiate from placebo on the primary endpoint
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Haloperidol
(Haldol)
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Fluoxetine
(Prozac)

• Clinical Global Impressions (CGI) Improvement Item: 3 out of 6 patients rated as responders
• Children's Psychiatric Rating Scale (CPRS): Subjects showed improvement on the CPRS Autism
Factor (P= 0.0008)
• Children's Yale-Brown Obsessive Compulsive Scale, modified for pervasive developmental
disorder (CYBOCS-PDD): 3.72-point reduction in mean score for treatment group, as compared
with a 2.53-point decrease in placebo group

7

Venlafaxine
(Effexor)

• Aberrant Behavior Checklist (ABC), Behavior Problems Inventory (BPI): multivariate analyses
showed the venlafaxine population to have lower values with respect to the placebo

• Sedation and drowsiness

• Autism Relevant Subscale of the Children's Psychiatric Rating Scale: Clomipramine was
superior to both placebo and desipramine on ratings of autistic symptoms (including
stereotypies), anger, and compulsive, ritualized behaviors (P < .05)

• Sedation, hostility, impatience, hyperactivity

• Conners Hyperactivity Index: minimum 50% decrease, ratings of stereotypy and inappropriate
speech also decreased

• Social withdrawal and irritability
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Clomipramine
(Anafranil)
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Methylphenidate
(Ritalin)

Atypical antipsychotic

Typical antipsychotic

SSRI

SNRI

TCA

Stimulant

• Weight gain, sedation, somnolence, vomiting

• Weight gain and sedation
• Dyskinesias incidence: 33.9%, majority reversible
• Risk of tardive dyskinesia
• Irritability, mood disturbance, nausea, vomiting, and sleep
disorders

